

## Summary of minutes of EUCAST Steering Committee Meeting Copenhagen, Denmark, 12-13 June 2006

**Attending**

Jenny Andrews	JA	BSAC	United Kingdom
Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Rafael Canton	RC	Clinical Data Co-ordinator	Spain
Dr Fred Goldstein	FG	SFM	France
Prof Gunnar Kahlmeter	GK	Chairperson	Sweden
Dr Johan W. Mouton	JM	CRG	The Netherlands
Prof Inga Odenholt	IO	SRGA	Sweden
Prof Arne Rodloff	AR	DIN	Germany
Dr Martin Steinbakk	MS	NWGA	Norway
Dr Olga Stetsiouk	OS	EUCAST	Russia
Prof Pietro Varaldo	PV	EUCAST	Italy

**Apologies**

Prof Waleria Hryniewicz	WH	EUCAST	Poland
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom

**Present for item 17**

Todd Black	TB	Schering-Plough Research Institute, USA
Radhouane Cherif	RCS	Schering-Plough Europe
Paul Mc Nicholas	PM	Schering-Plough Research Institute, USA

<b>1</b>	<b>Chairman's welcome</b> JA represented BSAC in place of AM. GK Welcomed WH and PV as new representatives of the EUCAST General Committee and RC in the new post of Clinical Data Co-ordinator.
<b>2</b>	<b>Minutes of meeting of 30-31 March 2006</b> With minor corrections the minutes were accepted as a correct record.
<b>3</b>	<b>Matters arising from minutes of 30-31 March 2006</b> Reference for rationale document supporting a high dose of cefotaxime/ ceftriaxone for central nervous system infections with pneumococci has been provided by JM.  Review of EUCAST website is continuing.  For amoxicillin-clavulanate MICs on the EUCAST website, data from only one source uses a fixed concentration and all others use a 2:1 ratio.  Rationale documents continue to be developed.  Version numbers will be included in breakpoint tables at the top of the document.  A draft tigecycline technical note has been produced.  Breakpoint tables for cephalosporins, carbapenems and aztreonam have been released. Exception notes for cefuroxime are expected from DIN and NWGA.  Inhibitor concentrations in $\beta$ -lactamase inhibitor combinations will be given in a footnote.  Oral and parenteral penicillins will be included in separate tables.  Footnote on methicillin resistant staphylococci has been applied to cephalosporin and carbapenem breakpoint tables also.  Agreed to leave ampicillin-sulbactam in the tables but not to set a breakpoint at the moment.  Comments on notes of dalbavancin, ceftobiprole and doripenem presentations reviewed.

4	<p><b>Temocillin</b> Eumedica are asking for a BSAC breakpoint only at present.</p>
5	<p><b>Tigecycline</b> The technical note for CMI is almost complete. The rationale document needs more work.</p>
6	<p><b>Daptomycin rationale document</b> This is essentially complete and will be put on the EUCAST website after checking.</p>
7	<p><b>Linezolid rationale document</b> This is essentially complete and will be put on the EUCAST website after checking.</p>
8	<p><b>Cephalosporin technical note</b> Agreed to update latest version and distribute to Steering Committee for comment.</p>
9	<p><b>Other rationale documents</b> RC will manage the progress of rationale documents/technical notes in the future.</p>
10	<p><b>European Food Safety Authority (EFSA)</b> Noted that the EFSA would use EUCAST epidemiological cut-offs for their surveillance studies. Comments were made on a draft methodology and list of agents to test.</p>
11	<p><b>ECCMID 2007, Munich</b> The EUCAST contribution to this meeting is not yet agreed.</p>
12	<p><b>Expert rules Subcommittee</b> No information on progress.</p>
13	<p><b>Macrolide breakpoints</b> A draft table was reviewed.</p>
14	<p><b>Fluconazole breakpoints and rationale document</b> An AFST Sub-committee draft document was reviewed and several amendments proposed.</p>
15	<p><b>ISO/CEN</b> AR has proposed that a reference method for antifungal susceptibility testing be defined and is awaiting a response. The reference broth microdilution method is expected to go out for vote in mid-July. The document on assessment of in-vitro devices was currently out for first vote and comment. A proposal for an ISO document on breakpoint setting would be raised at the ISO October meeting in Berlin.</p>
16	<p><b>Penicillin breakpoints</b> The draft table was reviewed taking into account comments from national committees. The table will be updated for further discussion.</p>
17	<p><b>Garenoxacin</b> A preliminary presentation of garenoxacin was made by PM.</p>
18	<p><b>Any other business</b> Retapamulin epidemiological breakpoints may be considered but clinical breakpoints will not be determined by EUCAST at this stage. EMEA and Industry to be notified.</p>
19	<p><b>Next meetings</b> 11-12 September 2006. Munich; 20-21 November 2006. Rome; 29-30 January 2007. Venue to be agreed; 3-4 April 2007 Munich (after ECCMID) ; 11-12 June 2007. Venue to be agreed; 6-7 September 2007. Venue to be agreed; 19-20 November 2007. Venue to be agreed.</p>

Summary of ratified minutes of meeting 12-13 June 2006 prepared by DB and GK